ArticleBlood2008
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 47 citations in OpenAlex.
- In-silico identification of genetic variants associated with chronic lymphocytic leukemia for diagnostic and therapeutic applications.Scientific reports · 2026Article
- The risk of reactivity against healthy tissues: Novel CARs demand testing for overlooked binding properties.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Physiological and Pathophysiological Roles of IgM Fc Receptor (FcµR) Isoforms.International journal of molecular sciences · 2023Review
- Immunoglobulin M perception by FcμR.Nature · 2023Article
- Soluble Fc Receptor for IgM in Sera From Subsets of Patients With Chronic Lymphocytic Leukemia as Determined by a New Mouse Monoclonal Antibody.Frontiers in immunology · 2022Article
- Distinct prognostic values of Annexin family members expression in acute myeloid leukemia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Article
- Functional Roles of the IgM Fc Receptor in the Immune System.Frontiers in immunology · 2019Review
- Role of the IgM Fc Receptor in Immunity and Tolerance.Frontiers in immunology · 2019Review
- Surface receptor Toso controls B cell-mediated regulation of T cell immunity.The Journal of clinical investigation · 2018Article
- Toso regulates differentiation and activation of inflammatory dendritic cells during persistence-prone virus infection.Cell death and differentiation · 2015Article
- Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.Cancer research · 2014Article
- Monoclonal antibodies specific for human IgM Fc receptor inhibit ligand-binding activity.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2014Article
- The long elusive IgM Fc receptor, FcμR.Journal of clinical immunology · 2014Review
- Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers.Medical oncology (Northwood, London, England) · 2013Article
- Involvement of Toso in activation of monocytes, macrophages, and granulocytes.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Article
- Overexpression of Fc mu receptor (FCMR, TOSO) gene in chronic lymphocytic leukemia patients.Medical oncology (Northwood, London, England) · 2012Article
- Article
- TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
To identify novel genes involved in the molecular pathogenesis of chronic lymphocytic leukemia (CLL) we performed a serial analysis of gene expression (SAGE) in CLL cells, and compared this with healthy B cells (nCD19(+)). We found a high level of similarity among CLL subtypes, but a comparison of CLL versus nCD19(+) libraries revealed 55 genes that were over-represented and 49 genes that were down-regulated in CLL. A gene ontology analysis revealed that TOSO, which plays a functional role upstream of Fas extrinsic apoptosis pathway, was over-expressed in CLL cells. This finding was confirmed by real-time reverse transcription-polymerase chain reaction in 78 CLL and 12 nCD19(+) cases (P < .001). We validated expression using flow cytometry and tissue microarray and demonstrated a 5.6-fold increase of TOSO protein in circulating CLL cells (P = .013) and lymph nodes (P = .006). Our SAGE results have demonstrated that TOSO is a novel over-expressed antiapoptotic gene in CLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.